English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/81627
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorCrespo-Facorro, Benedicto-
dc.contributor.authorPérez-Iglesias, Rocío-
dc.contributor.authorMata, Ignacio-
dc.contributor.authorValdizán, Elsa M.-
dc.contributor.authorVázquez-Barquero, J. L.-
dc.date.accessioned2013-09-09T07:46:44Z-
dc.date.available2013-09-09T07:46:44Z-
dc.date.issued2013-
dc.identifierdoi: 10.1097/JCP.0b013e3182825c1e-
dc.identifierissn: 0271-0749-
dc.identifiere-issn: 1533-712X-
dc.identifier.citationJournal of Clinical Psychopharmacology 33(2): 215-220 (2013)-
dc.identifier.urihttp://hdl.handle.net/10261/81627-
dc.descriptionet al.-
dc.description.abstractDifferences among antipsychotics in effectiveness have turned out to be a topic of increasing research interest, although comparisons between the different second-generation antipsychotics are scarce. From October 2005 to March 2011, a prospective, randomized, open-label study comparing the effectiveness of aripiprazole, ziprasidone, and quetiapine in the short-term treatment of first-episode schizophrenia-spectrum disorders was undertaken. Two hundred two patients were randomly assigned to aripiprazole (n = 78), ziprasidone (n = 62), or quetiapine (n = 62) and followed up for 6 weeks. The primary effectiveness measure was all-cause of treatment discontinuation. In addition, an analysis based on per protocol populations was conducted in the analysis for clinical efficacy. The overall dropout rate at 6 weeks was small (6.4%). The treatment discontinuation rate differed significantly between treatment groups (aripiprazole, 15%; ziprasidone, 19%; and quetiapine, 35%; χ = 8.529; P = 0.014). Insufficient efficacy in the group of quetiapine is the main reason for discontinuation rate differences (χ = 10.139; P = 0.006). The mean time to all-cause discontinuation was significantly different between the groups (log-rank, 12.783; P = 0.001). Quetiapine was associated with a greater depressive symptoms improvement than ziprasidone (P = 0.045). The rate of responders at 6 weeks differed between the groups (F = 6, 116; P = 0.047), with a higher rate of the responders with aripiprazole. The profile of adverse effects varies between the treatments. Patients on quetiapine were less likely to be prescribed concomitant medications. Treatment with quetiapine was associated with a higher risk of treatment discontinuation during treatment owing to insufficient efficacy. Differences in effectiveness between second-generation antipsychotics would determine their position in everyday clinical practice and could help physicians choose the more efficacious antipsychotics. © 2013 Lippincott Williams & Wilkins.-
dc.description.sponsorshipThe present study was carried out at the Hospital Marqués de Valdecilla, University of Cantabria, Santander, Spain, under the following grant support: Instituto de Salud Carlos III PI020499, PI050427, PI060507; Plan Nacional de Drugs Research Grant 2005-Orden sco/3246/2004, SENY Fundació Research Grant CI 2005-0308007; and Fundación Marqués de Valdecilla API07/011. Unrestricted educational and research grants from AstraZeneca, Pfizer, Bristol-Myers Squibb, and Johnson & Johnson provided support to PAFIP activities.-
dc.language.isoeng-
dc.publisherLippincott Williams & Wilkins-
dc.rightsclosedAccess-
dc.titleAripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: Results of a 6-week, randomized, flexible-dose, open-label comparison-
dc.typeartículo-
dc.identifier.doihttp://dx.doi.org/10.1097/JCP.0b013e3182825c1e-
dc.date.updated2013-09-09T07:46:44Z-
dc.description.versionPeer Reviewed-
dc.contributor.funderInstituto de Investigación Marqués de Valdecilla-
dc.contributor.funderUniversidad de Cantabria-
dc.contributor.funderInstituto de Salud Carlos III-
dc.contributor.funderJohnson and Johnson Pharmaceutical Research and Development-
dc.contributor.funderFundació Seny-
dc.contributor.funderAstraZeneca-
dc.contributor.funderPfizer-
dc.contributor.funderBristol Myers Squibb Foundation-
dc.relation.csic-
dc.identifier.funderhttp://dx.doi.org/10.13039/501100006365es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/100004325es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/100004319es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/100001009es_ES
Appears in Collections:(IBBTEC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.